Mohs微创手术治疗原发性皮肤粘液性癌。
Mohs Micrographic Surgery for the Treatment of Primary Cutaneous Mucinous Carcinoma.
发表日期:2023 Feb 14
作者:
Aine Kelly, Rakesh Anand, Jana Natkunarajah, Venura Samarasinghe, Emma Craythorne
来源:
CLINICAL AND EXPERIMENTAL DERMATOLOGY
摘要:
原句:Primary cutaneous mucinous carcinoma (PCMC) is a rare adnexal tumour of the skin. Clinically, it appears as a benign cyst; but it has characteristic histopathology. It is a slow-growing tumour that rarely metastasises but is associated with significant morbidity due to its high recurrence rate. Standard practice has been to surgically remove it with a wide local excision of 1 to 2 cm margin. In the last decade, increasing reports of Mohs micrographic surgery (MMS) for the treatment of PCMC carcinoma have been described. This appears to reduce recurrence rates whilst allowing for more conservative margins. Given the rarity of this tumour, there are no prospective randomised control trials on treatment. This is the largest case series of PCMC treated by MMS to date.
原文翻译:原发性皮肤黏液癌(PCMC)是皮肤的一种罕见附属肿瘤。在临床上,它看起来像是良性囊肿,但具有特征性的组织病理学。它是一种缓慢生长的肿瘤,很少转移,但由于其高复发率而与显著的发病率相关。常规处理是切除并进行 1 至 2 厘米较宽的局部切除。在过去十年中,越来越多关于用莫氏显微镜手术(MMS)治疗 PCMC 癌症的报告被描述出来。这似乎可以降低复发率,同时允许较为保守的切缘。由于这种肿瘤的罕见性,目前没有关于治疗的前瞻性随机对照试验。这是迄今为止使用 MMS 治疗 PCMC 的最大病例系列。© Crown copyright 2023.
Primary cutaneous mucinous carcinoma (PCMC) is a rare adnexal tumour of the skin. Clinically, it appears as a benign cyst; but it has characteristic histopathology. It is a slow-growing tumour that rarely metastasises but is associated with significant morbidity due to its high recurrence rate. Standard practice has been to surgically remove it with a wide local excision of 1 to 2 cm margin. In the last decade, increasing reports of Mohs micrographic surgery (MMS) for the treatment of PCMC carcinoma have been described. This appears to reduce recurrence rates whilst allowing for more conservative margins. Given the rarity of this tumour, there are no prospective randomised control trials on treatment. This is the largest case series of PCMC treated by MMS to date.© Crown copyright 2023.